The Shape of

Two-Step Injections

Maggie® is an easy-to-use, cartridge-based autoinjector built with SHL’s proprietary Needle Isolation Technology (NIT®). 

Join us at the 2020 PDA Universe of Pre-Filled Syringes and Injection Devices 

Join us at the 2020 PDA Universe

of  Pre-Filled Syringes and Injection Devices 

Oct 5-8

Virtual Event

Maggie®

Transform your cartridge-based treatment with Maggie®, a two-step autoinjector built with SHL’s proprietary Needle Isolation Technology (NIT®).

Needle Isolation Technology

Close

NIT® is a unique safety solution that makes it possible for cartridges to function like traditional pre-filled syringes with staked needles. Cartridges support higher volume dosing and enable dual-chamber treatments to be built as easy-to-use autoinjectors.

Higher Volume Injections

Close

Maggie® is built with a 3mL standard ISO cartridge to support the growing trend for high-volume dosing with the emergence of biologics and biosimilars. Cartridges also offer a level of needle customization for subcutaneous or intramuscular injections.

Automated Preparation

Close

Maggie®’s NIT® sub-assembly includes a pre-attached needle. Users simply untwist the cap to attach the needle and open the fluid path. The needle cover automatically extends and the autoinjector automatically primes.

Easy 2-Step Handling

Close

Injection with Maggie® is completed with just two simple steps: uncap and inject. The autoinjector needle cover locks out after injection, shielding patients from being exposed to te needle before and after injection.

Intuitive Feedback

Close

Maggie®’s large viewing window makes it easier for patients to inspect the drug before and during injection. It also features continuous audible clicks during injection, resulting in an easier determination of dose completion.

© 2020 SHL Medical AG. SHL, the SHL logo, and all other trademarks are property of SHL Medical AG and/or its affiliates.

Intuitive Feedback

Maggie®’s large viewing window makes it easier for patients to inspect the drug before and during injection. It also features continuous audible clicks during injection, resulting in an easier determination of dose completion.

Easy 2-Step Handling

Injection with Maggie® is completed with just two simple steps: uncap and inject. The autoinjector needle cover locks out after injection, shielding patients from being exposed to the needle before and after injection.

Automated Preparation

Maggie®’s NIT® sub-assembly includes a pre-attached needle. Users simply untwist the cap to attach the needle and open the fluid path. The needle cover automatically extends and the autoinjector automatically primes.

Higher Volume Injections

Maggie® is built with a 3mL standard ISO cartridge to support the growing trend for high-volume dosing with the emergence of biologics and biosimilars. Cartridges also offer a level of needle customization for subcutaneous or intramuscular injections.

Needle Isolation Technology

NIT® is a unique safety solution that makes it possible for cartridges to function like traditional pre-filled syringes with staked needles. Cartridges support higher volume dosing and enable dual-chamber treatments to be built as easy-to-use autoinjectors.

Go to article: Home | Antibiotic AdjacentGo to article: In this issueGo to article: ContentsGo to article: SHL Company InsightGo to article: SHL MedicalGo to article: TiveGo to article: Controlant Company InsightGo to article: ControlantGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: L.B. Bohle MaschinenGo to article: L.B Bohle Company InsightGo to article: ACG WorldwideGo to article: CommentGo to article: HPV infections drop due to widespread vaccinationGo to article: Europe reports the highest prevalence of chronic cough across the 7MMGo to article: How could vaccine hesitancy affect the prevalence of hearing disorders?Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: RegPakGo to article: PfeifferGo to article: In DepthGo to article: Antibiotic adjacent: the alternatives tackling AMR Go to article: Regenerative medicine: ready for the big leagues? Go to article: Human challenge trials: pandemic exit strategy or ethical nightmare?Go to article: Drug dispensing goes digitalGo to article: Could this Novartis initiative finally cure sickle cell disease?Go to article: Centessa Pharmaceuticals: forging a new path for pharma R&DGo to article: Biomax Company InsightGo to article: BiomaxGo to article: DuojectGo to article: Duoject Company InsightGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: MyonexGo to article: BaxterGo to article: EventsGo to article: Next issue